MedTrace Logo

Single and Multiple Dose Study of VER-01 in Healthy Volunteers

NCT04930809 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-07-14

No results posted yet for this study

Summary

Evaluation of pharmacokinetics, tolerability and safety of VER-01 in healthy volunteers

Conditions

  • Healthy

Interventions

DRUG

VER-01

standardised cannabis extract (containing 21 mg THC per gram drug product)

Sponsors & Collaborators

  • Vertanical GmbH

    lead INDUSTRY

Principal Investigators

  • Michael Wolzt, Professor · University of Medicine in Vienna - Department of Clinical Pharmacology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-25
Primary Completion
2022-07-04
Completion
2022-07-11

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04930809 on ClinicalTrials.gov